LAS1L

Ribosomal biogenesis protein LAS1L · Q9Y4W2 · LAS1L on Sugi Atlas →

0 patent compounds predicted against LAS1L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LAS1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab PHASE4UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis PHASE2COMPLETED
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE1WITHDRAWN
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome PHASE1COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS) nanRECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Impact of Bariatric and Metabolic Surgery on the Reduction of Premature Aging. nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LAS1L binder may also engage these)

ProteinNameSimilarity
A2BE28 0.993 A2BE28 →
Q9Z2U2 0.988 Q9Z2U2 →
O88480 0.986 O88480 →
Q8IZM8 0.985 Q8IZM8 →
Q7Z7J5 0.985 Q7Z7J5 →
Q99ME3 0.985 Q99ME3 →
Q3UMB5 0.985 Q3UMB5 →
Q9DAU9 0.984 Q9DAU9 →
Q8TEV9 0.984 Q8TEV9 →
GSAP Gamma-secretase-activating protein 0.984 landscape →
Q80TQ5 0.984 Q80TQ5 →
Q13129 0.984 Q13129 →
Q6INI0 0.984 Q6INI0 →
Q8IWE5 0.984 Q8IWE5 →
Q76N89 0.984 Q76N89 →
A2AHC3 0.984 A2AHC3 →
A6QLA6 0.983 A6QLA6 →
Q6DRL4 0.983 Q6DRL4 →
Q3UJB9 0.983 Q3UJB9 →
Q9Y4F4 0.983 Q9Y4F4 →
Q5F479 0.983 Q5F479 →
O18805 0.983 O18805 →
Q8BL06 0.983 Q8BL06 →
CECR2 Chromatin remodeling regulator CECR2 0.983 landscape →
Q8N4X5 0.983 Q8N4X5 →
Q5XG73 0.983 Q5XG73 →
B1H224 0.983 B1H224 →
Q8BW88 0.983 Q8BW88 →
Q8VDP4 0.982 Q8VDP4 →
Q76LL6 0.982 Q76LL6 →